AER001

DB05078InvestigationalSmall molecule

AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.

Primary indication
Investigated for use/treatment in asthma.Curator reviewed
Code names
AER001

Resolves to

Targets
P24394IL4RQ14627IL13RA2

What you can answer from here — as of April 02, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which drugs share a target with AER001, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In